Volume 2, Issue 1, June 2018, Page: 6-14
Perspectives of Plasmapheresis in the Treatment of Kidney Diseases
Valerii Alexandrovich Voinov, Gravitation Blood Surgery Department, I. P. Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
Konstantin Stepanovich Karchevsky, Gravitation Blood Surgery Department, I. P. Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
Oleg Valerievich Isaulov, Gravitation Blood Surgery Department, I. P. Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
Received: May 30, 2018;       Accepted: Jun. 22, 2018;       Published: Jul. 21, 2018
DOI: 10.11648/j.ijcu.20180201.12      View  575      Downloads  39
Abstract
Many kidney diseases pose a serious threat to human health and even life. In some cases, they inevitably lead to hemodialysis and even the need for kidney transplantation. Almost all chronic kidney disease in varying degrees, are associated with disorders of the internal environment, mainly autoimmune nature. Drug therapy is not always effective and can lead to additional disorders. Pathogenetically justified is the use of plasmapheresis. The aim of this study was to analyze the modern world literature in order to identify the features of the pathogenesis and course of various forms of chronic kidney disease in terms of determining the possibility of using plasmapheresis and indications for it. With the help of plasmapheresis, a number of problems can be solved in urology, in particular in the treatment of pyelonephritis, prostatitis and even male infertility.
Keywords
Kidney Diseases, Autoimmunity, Plasmapheresis, Male Infertility
To cite this article
Valerii Alexandrovich Voinov, Konstantin Stepanovich Karchevsky, Oleg Valerievich Isaulov, Perspectives of Plasmapheresis in the Treatment of Kidney Diseases, International Journal of Clinical Urology. Vol. 2, No. 1, 2018, pp. 6-14. doi: 10.11648/j.ijcu.20180201.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Chandnani HK, Jain R, Patamasucon P. Group C streptococcus causing rheumatic heart disease in a child. J Emerg Med 2015; 49; 12-14.
[2]
Fisher A. Die Wandlung der postinfektiösen Glomerulonephritis. Ther Umsch 2015; 72: 141-147.
[3]
Haris A, Arányi J, Braunitzer H et al. Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions. Orv Hetil 2011; 152 (28): 1110-1119.
[4]
Reddy SK, Jahan A, Chaturvedi S, Agarwal I. Plasma exchange for paediatric kidney disease-indications and outcomes: a single-centre experience. Clin Kidney J 2015; 8 (6): 702-707.
[5]
Couzi L, Morel D, Deminière C, Merville P. An unusual endocarditis-induced crescentic glomerulonephritis treated by plasmapheresis. Clin Nephrol 2004; 62 (6): 461-464.
[6]
Müller-Deile J, Schiffer M. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015; 45 (12): 1260-1269.
[7]
Subramaniam SR, Cader RA, Mohd R et al. Low-dose cyclophosphamide-induced acute hepatotoxicity. Am J Case Rep 2013; 4 (14): 345-349.
[8]
Halpin M, Kozyreva O, Bijol V, Jaber BL. Plasmapheresis for treatment of immune complex-mediated glomerulonephritis in infective endocarditis: a case report and literature review. Clin Nephrol Case Study 2017; 5: P. 26-31.
[9]
Walsh M, Catapano F, Szpirt W et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: meta-analysis. Am J Kidney Dis 2011; 57 (4): 566-574.
[10]
Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J 2015; 8 (2): 143-150.
[11]
Chen Y, Yang L, Li K et al. Double filtration plasmapheresis in the treatment of antineutrophil cytoplasmic autoantibody associated vasculitis with severe renal failure: a preliminare study of 15 patients. Ther Apher Dial 2016; 20 (2): 183-188.
[12]
Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 7: P. 2180-2188.
[13]
Milovanov YuS, Komyagin YuV, Nikolaev AYu [Plasmapheresis in treatment of quickly progressing glomerulonephritis. Ther Arch (Rus) 1993; 6: 80-86.
[14]
Fujigaki Y, Morimoto C, Iino R, Taniguchi K, Rawamotrita Y et al. Discontinuation of hemodialysis in a patient with anti-GBM disease by the treatment with corticosteroids and plasmapheresis despite several predictors for dialysis-dependence. Case Rep Nephrol 2017; 2017: 7143649.
[15]
Usui T, Kai H, Noguchi K et al. Effectiveness of plasmapheresis in a patient with anti-glomerular basement membrane antibody glomerulonephritis with advanced kidney dysfunction. Intern Med 2017; 56 (18): 2475-2479.
[16]
Adnan MM, Morton J, Hashmi S et al. Anti-GBM disease in pregnancy: Acute renal failure resolved after plasma exchange, hemodialysis, and steroids. J Investig Med High Impact Case Rep 2015; 31 (4): 2314709615624232.
[17]
Mallett A, Tang W, Hart G et al. End-stage kidney disease due to fibrillary glomerulonephritis and immunotactoid glomerulopathy – outcomes in 66 consecutive ANZDATA Registry Cases. Am J Nephrol 2015; 42 (3): 177-184.
[18]
Cheungpasitporn W, Zacharek CC, Fervenza FC et al. Rapidly progressive glomerulonephritis due to coexistent antiglomerular basement membrane disease and fibrillary glomerulonephritis. Clin Lidney J 2016; 9 (1): 97-101.
[19]
Pliquett RU, Mohr P, Mukhtar BD et al. Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report. J Med Case Rep 2012; (6): 116.
[20]
Nord AT, Nord BL, Schmidt AE, Smith DS. Management of Dense Deposit Disease with Plasmapheresis and eculizumab. J Clin Apher 2014; 29 (1): 28-29.
[21]
Russo GE, Bonello M, Bauco B et al. Nephrotic syndrome and plasmapheresis. Int J Artif Organs 2000; 23 (2): 111-113.
[22]
Kobayashi T, Ando Y, Umino T et al. Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 2006; 65 (6): 423-426.
[23]
Zhang YY, Tang Z, Chen DM et al. Comparison of double filtration plasmapheresis with immunoadsorbtion therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014; 15: 128.
[24]
Clark W. F. Plasma exchange for renal disease: evidence and use 2011// J. Clin. Apher. – 2012 27; (3): 112-116.
[25]
Clark WF, Huang SS, Walsh MW et al. Plasmapheresis for the treatment of kidney disease. Kidney Int 2018; 90 (5): 974-984.
[26]
Wieliczko M, Dylewska M. IgA nephropathy – prognostic factors and treatment. Wiad Lek 2016; 69 (5): 707-710.
[27]
Lechner SM, Papista C, Chemouny JM et al. Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol 2016; 29 (1): 5-11.
[28]
Trimarchi H, Barratt J, Cattran DC et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91 (5): 1014-1021. 28.
[29]
Stefan G, Ismail G, Stancu S et al. Validation study of Oxford Classification of IgA Nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining. Pathol Int 2016; 66 (8): 453-459.
[30]
Xie X, Ly J, Shi S et al. Plasma exchange as an adjuvant therapy for crescentic IgA nephropathy. Am J Nephrol 2016; 44 (2): 141-149.
[31]
Saad M, Daoud M, Nasr P et al. IgA-dominant post-infectious glomerulonephritis presenting as a fatal pulmonary-renal syndrome. Int J Nephrol Renovasc Dis 2015; (8): 77-81.
[32]
Yim DK, Lee ST, Cho H. Plasmapheresis therapy for pulmonary hemorrhage in a pediatric patients with IgA nephropathy. Korean J Pediatr 2015; 58 (10): 402-405.
[33]
Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am 2014; 32 (3): 649-671.
[34]
Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Tromb Haemost 2018; 16 (4.): 618-629.
[35]
Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 2009; 9 (1): 36-50.
[36]
Hidebrand AM, Huang SH, Clark WF. Plasma exchange for kidney disease: what is the best evidence? Adv Chronic Kidney Dis 2014; 21 (2): 217-227.
[37]
Nakanishi T, Suzuki N, Kuragano T et al. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 2014; 18 (1): 41-49.
[38]
Martins I, Conceição MG, Gomes PP, Clode N. Hemolysis, elevated liver enzymes, low platelets syndrome superimposed on hemolytic uremic syndrome. Pev Bras Ginecol Obstet 2017; 39 (4): 195-198.
[39]
Winiarska A, Kwella N, Stompór T. Heparin-unduced thrombocytopenia as a course of prolonged low platelet count in a patient with thrombotic thrombocytopenic purpura treated with plasmapheresis. Acta Biochim Pol 2017; 64 (2): 375-376.
[40]
Sharma RK, Kaul A, Agrawal V, Jaisuresh K. Primapy antiphospholipid syndrome presenting as thrombotic microangiopathy: Successful treatment wiyh steroids, plasma exchange and anticoagulants. Indian J Nephrol 2011; 21 (4): 280-282.
[41]
Ryu H, Kang E, Park S et al. A case of gemcitabine-induced thrombotic microangiopathy in a urogenital tumor patient with a single kidney. Kidney Res Clin Pract 2015; 34 (4): 237-340.
[42]
Chen KR, Carlson JA Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9 (2): 71-92.
[43]
Nissaisorakarn P, D’Agati V, Anis K, Jim B. ANCA and IgA glomerulonephritis all in one: prognosis and complications. BMJ Case Rep 2017; 2017: 222080.
[44]
Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017; 12 (11): P. 1680-1691.
[45]
Popovic D, Pjeakovic S, Rankov O et al. Diabetic nephropathy in pregnant women with type 1 diabetes (multiple cases review and discussion. Georgian Med News 2018; 277: 15-20.
[46]
Akhter F., Khan M. S., Alatar A. A. et al. Antigenic role of the adaptive immune response to d-ribose glycated LDL in diabetes, atherosclerosis and diabetes atherosclerotic patients. Life Sci 2016; 151: 139-146.
[47]
Hickey FB, Martin F. Role of the immune system in diabetic kidney disease. Curr Diab Rep 2018; 18 (4): 20.
[48]
Gul A, Zager P. Does altered uruc acid metabolism contribute to diabetic kidney disease pathophisiology. Curr Diab Rep 2018; 18 (4): 18.
[49]
Sagoo MK, Gnudi L. Diabetic nephropathy: is there a role for oxidative stress? Free Radic Biol Med 2018; 116: 50-63.
[50]
Bjornstad P, Cherney DZ. Renal hyperfiltration in adolescents with type 2 diabetes: physiology, sex differences, and implications for diabetic kidney disease. Curr Diab Rep 2018; 18 (5) 22.
[51]
Bus P, Chua JS, Lkessens CQF et al. Complement activation in patients with diabetic nephropathy. Kidney Int Rep 2017; 3 (2): 302-313.
[52]
Lutfi R, Huang J, Wong HP. Plasmapheresis to treat hypertriglyceridemia in a child with diabetic ketoacidosis and pancreatitis. Pediatrics 2012; 129 (1): e195-198.
[53]
Hardt U, Larsson A, Gunnarsson I et al. Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Res Ther 2018; 20 (1): 36.
[54]
Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine (Baltimore) 2016; 95 (18): e3595.
[55]
Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. 2016; 15 (1): 38-49.
[56]
Li M, Wang Y, Qiu Q et al. Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis. J Clin Apher 2016; 31 (4): 375-380.
[57]
Nakano T, Nagae H, Murakami N et al. Fever associated with severe dialysis- related amyloidosis. CEN Case Rep 2012; 1 (2): 112-116.
[58]
Matsumoto K, Kikuchi J, Kaneko Y et al. Persistent fever and destructive arthritis caused by dialysis-related amyloidosis: a case report. Medicine (Baltimore) 2018; 97 (1): e9359.
[59]
Joseph A, Harel S, Venot M et al. Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. Clin Kidney J 2018; 11 (1): 20-25.
[60]
Scarpato S, Tirri E, Naclerio C et al. Plasmapheresis in cryoglobulinemic neuropathy: a clinical study. Dig Liver Dis 2007; 39, Suppl l (1) S136-137.
[61]
Niaudet P. [Hemolytic and uremic syndrome in the child]. Nephrol Ther 2008; 4 (1): 34-40 (Fr).
[62]
Amirlak I, Amirlak B. Haemolytic uraemic syndrome: an overview. Nephrology (Carlton) 2006; 11 (3): 213-218.
[63]
Van Gemert LM, Montemayor-Garcia C, Rose WN. Dramatic improvement immediately after plasma exchange in a patient with Shiga toxin-producing Escherichia Coli hemolytic uremic syndrome. J Clin Apher 2014; 29 (1): 46.
[64]
Loos S, Aulbert W, Hoppe B et al. Intermediat follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 2017; 64 (122): 1637-1643.
[65]
Kielstein JT, Beutel G, Fieig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012: 27 (10): 3807-3815.
[66]
Ozkok A, Yildriz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20 (24): 7544-7554.
[67]
Balwani MR, Kute VB, Shah PR et al. Hepatitis B viremia manifesting as polyarteritis nodosa and secondary membranous nephropathy. J Nephropharmacol 2016; 5 (2): 119-121.
[68]
Mareddy AS, Rangaswamy D, Vankalakunti M et al. Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for common infection. Australas Med J 2016; 31 (1): 12-16.
[69]
Narayanan M, Casimiro I, Pichler R. A unique way to treat Goodpasture’s disease. BMJ Case Rep 2014; Nov 24: 2014206220.
[70]
Milovanov Yu S [Plasmapheresis in nephrology]. In: "Clinical application of extracorporeal treatments." Moscow, 2006: 72-75 (Rus).
[71]
Okuyama H, Kimura S, Fujimoto K et al. A case of chronic hepatitis C with nephrotic diabetic nephropathy who achived sustained viral remission by double-filtration plasmapheresis and interferon combination therapy. Intern Med 2012; 51: 1991-1995.
[72]
Shelukhin, VA, Kostyuchenko AL. [Apheresis therapy in diseases and lesions of the kidneys]. In: Efferent therapy/ edited by AL Kostyuchenko. St. Petersburg: Folio 2003: 268-302 (Rus).
[73]
Dovlatyan A. [Intensive care of complicated forms of purulent gestational pyelonephritis]. Urology 2008; 2: 10-14 (Rus).
[74]
Akhmedzhanova ZM, Vetrov VV, Konovalova MV, Taits AN. [Plasmapheresis and photomodification of blood in prevention of septic complications in puerperas]. Proc. Confer. "Therapeutic Hemapheresis" St. Petersburg 2017: 14-15. (Rus).
[75]
Neymark AI, Yakovets YaV, Astakhov YuI. [Plasmapheresis in correction of violations of a hemostasis system at patients with acute and chronic pyelonephritis]. Efferent Therapy (Rus) 1996; 2 (4): 45-49.
[76]
Crumley S, Ge Y, Zhou H et al. Interstitial cystitis: another IgG4-related inflammatory disease? Ann Diagn Pathol 2013; 17 (5): 403-407.
[77]
Lee J, Doggweiler-Wiygul R, Kim S et al. Is interstitial cystitis an allergic disorder? A case of cystitis treated successfully with anti-IgE. Int J Urol 2006; 13 (5): 631-634.
[78]
Boissier E, Durant C, Vildy S et al. An unexpected etiology of priapism: infection-related anti-proteins antibodies. J Sex Med 2014; 11 (11): 2830-2833.
[79]
Restrepo B, Cardona-Maya W. Antisperm antibodies and fertility association. Actas Urol Esp 2013; 37 (9): 571-578.
[80]
Tchiokadze Sh, Galdava G Clinical and anamnestic characteristics of development of antisperm immunity in infertile men. Georgian Med News 2015; 246: 18-22.
[81]
Drobnis EZ, Nangia AK. Immunosuppressants and male reproduction. Adv Exp Med Biol 2017; 1034: 179-210.
[82]
Benedetti S, Tagliamonte MC, Catalani S et al. Differences in blood and semen oxidative status in fertile and infertile men, and their relationship with sperm quality. Reprod Biomed Online 2012; 25 (3): 300-306.
[83]
Agarwal A, Durairajanayagam D, Halabi J et al. Proteomics, oxidative stress and male infertility. Reprod Biomed Online 2014; 29 (1): 32-58.
[84]
Ambulkar PS, Chuadhari AR, Pal AK. Association of large scale 4977-bp “common” deletions in sperm mitochondrial DNA with asthenozoospermia and oligoasthenoteratozoospermia. J Hum Reprod Sci 2016; 9 (1): 35-40.
[85]
Korenkov DG, Alexandrov VP, Marusanov VE et al. [Features of application of efferent methods at correction of immunodependent infertility at men. Efferent Therapy (Rus) 2003; 9 (2): 43-49.
[86]
Atyushev GP, Motavkina NS. [Viral infections in genesis of antispermal immunity and infertility at patients with urogenital infections, sexually transmitted]. Allergol Immunol (Rus) 2006; 7 (3): 391-392.
[87]
Tiseo BC, Cocuzza M, Bonfa F et al. Male fertility potential alteration in rheumatic diseases: a systematic review. Int Braz J Urol 2016; 42 (1): 11-21.
[88]
Dupree JM. Insuarance coverage for male infertility care in the United States// Asian J Androl 2016; 18 (3): 339-341.
[89]
Andrievskikh IA, Fokin AA, Grafov AA. [Effect of immunocorrection on surgical outcomes in patients with autoimmune-aetiology vasculitis and vasculopathies]. Angiol Sosud Khir (Rus) 2008; 14 (2): 20-26.
[90]
Gungor O, Sen S, Kircelli F et al. Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc 2011; 43: 853-857.
[91]
Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20 (22): 6716-6724.
[92]
Abbas A, Mitza MM, Ganti AK, Tendulkar K. Renal toxicities of targeted therapies. Target Oncol 2015; 10 (4): 487-499.
[93]
Okuda Y, Ishikura K, Terano C et al. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab. Nephrology (Carlton) 2016; 21 (3): 261-265.
[94]
Masmoudi A, Hajiaji Darouiche M, Ben Salah H et al. Cutaneous abnormalities in patients with end stage renal failure on chronic hemodialysis. A study of 458 patients. J Dermatol Case Rep 2014; 8: 86-94.
[95]
Fuhrmann V., Drilz A., Trauner M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. Liver Int 2011; 31 (Suppl. 3): 31-33.
[96]
Dechmann-Sultemeyer T, Linkeschova R, Lenztn K et al. Tandem plasmapheresis and haemodialisis as a safe procedure in 82 patients with immune-mediated disease. Nephrol Dial Transplant 2009; 24 (1): 252-257.
[97]
Loo CY, Mohamed Said MS, Mohd R et al. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 2010; 43 (3): 335-340.
[98]
Voinov VA. Therapeutic apheresis. Constanţa: Celebris. 2016: 400 p.
[99]
Voinov VA, Karchevsky KS, Isaulov OV. [Plasmapheresis in nephrology]. Nephrologia (Rus) 2017; Vol. 21 (4): 95-101.
Browse journals by subject